IL15 and neoplasm: In vivo studies revealed that CISH-/- iC9/CAR19/IL-15 CB-NK cells persisted twice as long as control CAR19/IL-15 NK cells and significantly improved anti-tumor responses since animal treated with CISH KO iC9/CAR19/IL-15 CB-NK cells were tumor free (181).